← Back to Clinical Trials
Recruiting NCT06184880

NCT06184880 Effect of Physical Activity Program on Sedentary of Patients With Upper Aerodigestive Tract Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06184880
Status Recruiting
Phase
Sponsor Centre Hospitalier de Valence
Condition Upper Aerodigestive Tract Cancer
Study Type INTERVENTIONAL
Enrollment 96 participants
Start Date 2024-03-19
Primary Completion 2029-10-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
behavioralSedentary

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 96 participants in total. It began in 2024-03-19 with a primary completion date of 2029-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

APAORL2 study aims to evaluate the efficacy of a physical activity program on the sedentary and physical activity level during the 18-month program. APAORL2 study is a randomized, open label, controlled, monocentric, intervention study that will be conducted among 96 patients treated for localized upper aerodigestive tract cancer.

Eligibility Criteria

Inclusion Criteria: * Patients ≥18 years * newly diagnosed, histologically proven Upper Aerodigestive Tract Cancer, non-metastatic, * life expectancy ≥18 months * having a smartphone, tablet or computer with an internet connection enabling remote physical Activity sessions for the experimental group Exclusion Criteria: * Presenting a contraindication to moderate physical activity * Deprived of their liberty by court or administrative decision * Unable to be followed for medical, social, family, geographic or psychological reasons for the duration of the study,

Contact & Investigator

Central Contact

Guillaume Buiret

✉ gbuiret@ch-valence.fr

📞 +33475752555

Principal Investigator

Guillaume Guillaume

PRINCIPAL INVESTIGATOR

CH VALENCE

Frequently Asked Questions

Who can join the NCT06184880 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Upper Aerodigestive Tract Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06184880 currently recruiting?

Yes, NCT06184880 is actively recruiting participants. Contact the research team at gbuiret@ch-valence.fr for enrollment information.

Where is the NCT06184880 trial being conducted?

This trial is being conducted at Valence, France.

Who is sponsoring the NCT06184880 clinical trial?

NCT06184880 is sponsored by Centre Hospitalier de Valence. The principal investigator is Guillaume Guillaume at CH VALENCE. The trial plans to enroll 96 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology